← All indications
Alopecia Areata
Loss of scalp and body hair involving microscopically inflammatory patchy areas.
Drugs by status
Approved for this indication (4)
Phase 4 trials (16)
Phase 3 trials (10)
Phase 2 trials (39)
- metronidazole
- vitamin d3
- secukinumab
- Farudodstat
- bisacodyl
- dupilumab
- jnj-64304500
- Brepocitinib
- ruxolitinib
- Remetinostat
- abatacept
- tralokinumab
- vancomycin
- ciprofloxacin
- human fecal microbiota
- ky1005
- crisaborole
- azathioprine
- loperamide
- ati-50002
- delgocitinib
- abrocitinib
- etrasimod
- Ifidancitinib
- bnz-1
- Stem Cell Educator
- jacatinib
- adx-914
- deucravacitinib
- nxc736
- +9 more
Phase 1 trials (13)
Organizations
Organization Involved with Phase 4 Indications (25)
- 3M
- Celgene
- Allergan
- Ain Shams University
- Cairo University
- Callender Center for Clinical Research
- King Saud University
- Postgraduate Institute of Medical Education and Research
- Skin Care and Laser Physicians of Beverly Hills
- University of Florida
- Wake Forest University
- Assiut University
- Columbia University
- Sohag University
- Stony Brook University
- Vanderbilt University
- Kafrelsheikh University
- Icahn School of Medicine at Mount Sinai
- University of Minnesota
- Callender Skin for Clinical Research
- Eclipse Aesthetics, LLC
- Saudi Society of Dermatology and Dermatologic surgery
- Bellevue Dermatology
- Institute of Dermatology, Thailand
- The Skin of Color Society
Organization Involved with Phase 3 Indications (27)
- Incyte
- Ligand Pharmaceuticals
- Stiefel Laboratories
- Merck
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Biosplice Therapeutics
- Polichem S.A.
- ViraCyte
- Concert Pharmaceuticals
- The Hospital for Sick Children
- Mae Fah Luang University Hospital
- Mahidol University
- Siriraj Hospital
- The New York Eye & Ear Infirmary
- University of Toronto
- University of Brasilia
- Free University of Berlin
- University of Texas at Houston
- University of Nice Sophia Antipolis
- Tabriz Medical University
- Humboldt University
- Dermatology Foundation
- Johnson and Johnson
- Rouen Normandy University
- National Alopecia Areata Foundation
Organization Involved with Phase 2 Indications (42)
- Aclaris Therapeutics, Inc.
- Aderans Research Institute
- Bristol-Myers Squibb
- Genentech
- Novartis
- Arena Pharmaceuticals
- Bharat Biotech International Limited
- Dong-A Pharmaceutical
- Energenesis Biomedical Co., Ltd.
- Intrepid Therapeutics, Inc.
- Merz
- Mitos Pharmaceuticals
- Neosil, Inc.
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Therapeutics, Inc.
- A2 Healthcare Taiwan Corporation
- Bioniz Therapeutics
- TetraLogic Pharmaceuticals
- University of Pennsylvania
- Rockefeller University
- Central South University
- Alexandria University
- Duke University
- King Edward Medical University
- Northwestern University
- Tufts University
- Yale University
- Mayo Clinic
- Tel Aviv University
- The Crown Institute
- +12 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (16)
- Galderma
- Applied Biology, Inc.
- Dream Plus
- National Cancer Institute (NCI)
- University of Roma La Sapienza
- Ablon Skin Institute Research Center
- Case Western Reserve University
- Hamamatsu University
- Kaiser Permanente
- Sadick Research Group
- Stanford University
- University of California, Los Angeles
- University of California, San Francisco
- Irish Response t/a Lifes2good
- Aswan University
- Pusan National University